We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
Read MoreHide Full Article
Key Takeaways
Bruker has acquired biocrates to enhance its MS-based quantitative metabolite analysis offerings.
The biocrates acquisition builds on BRKR's earlier buys of PreOmics and Biognosys in multiomics.
Biocrates kits cover 1,000 metabolites, aiding in biomarker discovery and precision healthcare.
Bruker Corporation (BRKR - Free Report) recently announced the acquisition of biocrates life sciences ag, a global leader in mass spectrometry (MS)-based quantitative metabolite analysis based in Innsbruck, Austria. However, the financial terms of the deal were not disclosed.
The latest development reflects the two companies’ shared passion for multiomics technologies. Biocrates has long been focused on supporting and innovating across multiple MS technologies and vendors, and joining Bruker is expected to scale its impact.
BRKR Stock’s Likely Trend Following the News
Since the June 3 announcement, shares of Bruker have risen 4.8%, finishing yesterday’s session at $39.21. Multiomics represents the foundation for the future of life sciences, biopharma R&D and clinical research, and biocrates adds key metabolomics solutions to the Bruker portfolio. The company can now support customers with a truly integrated multiomics approach through its services, software and kits for high-end proteomics and metabolomics. Accordingly, this should continue to boost the market sentiment surrounding BRKR stock.
Bruker has a market capitalization of $5.80 billion. Going by the Zacks Consensus Estimate, the company’s 2025 earnings are expected to increase 1.7%. In the trailing four quarters, it delivered an average earnings beat of 0.5%.
Significance of BRKR’s New Acquisition
The acquisition of biocrates further enhances Bruker’s MS-based metabolomics solutions. The biocrates kits cover more than 1,000+ metabolites from more than 40 metabolite classes, and the biocrates metabolomics technology platform integrates advanced sample preparation, metabolite identification and data analysis. Researchers worldwide rely on their flagship kits, such as MxP Quant 1000, to transform metabolic data from diverse tissues and sample types into clearer biomarkers, accelerate drug development and more precise healthcare.
Image Source: Zacks Investment Research
The acquisition also supports Bruker’s expansion into multiomics solutions, including instruments, reagents, software and research services, building on the prior acquisitions of proteomics kits, software and services companies PreOmics and Biognosys.
Industry Prospects Favoring Bruker Stock
Per a research report, the global metabolomics services market is estimated to be valued at $3.2 billion in 2025 and expand at a compound annual growth rate (CAGR) of 12.5% through 2032. The market’s growth is being led by growing applications of metabolomics in personalized medicines, drug discovery and development, biomarker discovery, nutrigenomics, and other fields such as toxicology and cancer. The rising R&D investments in pharmaceutical and biotechnology companies also contribute.
More Updates From Bruker
At the 73rd Conference on Mass Spectrometry and Allied Topics, Bruker announced significant advances in ultra-high sensitivity 4D-Proteomics with the introduction of the timsUltra AIP mass spectrometer. The breakthrough Athena Ion Processor technology further enhances the extreme sensitivity of timsTOF UltraPASEF methods for key biological and clinical research problems with very low sample amounts.
BRKR Stock Price Performance
Over the past three months, Bruker shares have declined 13.9% compared with the industry’s 14.3% fall.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 44.6% in the past year compared with the industry’s 9.6% growth. Its earnings yield of 8.5% compares comfortably with the industry’s 0.5% yield. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Hims & Hers Health shares have surged 158% in the past year. Estimates for the company’s 2025 earnings per share have jumped 4.3% to 73 cents in the past 30 days. HIMS’ earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.
Estimates for Cencora’sfiscal 2025 earnings per share have increased 1.3% to $15.75 in the past 30 days. Shares of the company have jumped 22.1% in the past year against the industry’s 21% fall. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
Key Takeaways
Bruker Corporation (BRKR - Free Report) recently announced the acquisition of biocrates life sciences ag, a global leader in mass spectrometry (MS)-based quantitative metabolite analysis based in Innsbruck, Austria. However, the financial terms of the deal were not disclosed.
The latest development reflects the two companies’ shared passion for multiomics technologies. Biocrates has long been focused on supporting and innovating across multiple MS technologies and vendors, and joining Bruker is expected to scale its impact.
BRKR Stock’s Likely Trend Following the News
Since the June 3 announcement, shares of Bruker have risen 4.8%, finishing yesterday’s session at $39.21. Multiomics represents the foundation for the future of life sciences, biopharma R&D and clinical research, and biocrates adds key metabolomics solutions to the Bruker portfolio. The company can now support customers with a truly integrated multiomics approach through its services, software and kits for high-end proteomics and metabolomics. Accordingly, this should continue to boost the market sentiment surrounding BRKR stock.
Bruker has a market capitalization of $5.80 billion. Going by the Zacks Consensus Estimate, the company’s 2025 earnings are expected to increase 1.7%. In the trailing four quarters, it delivered an average earnings beat of 0.5%.
Significance of BRKR’s New Acquisition
The acquisition of biocrates further enhances Bruker’s MS-based metabolomics solutions. The biocrates kits cover more than 1,000+ metabolites from more than 40 metabolite classes, and the biocrates metabolomics technology platform integrates advanced sample preparation, metabolite identification and data analysis. Researchers worldwide rely on their flagship kits, such as MxP Quant 1000, to transform metabolic data from diverse tissues and sample types into clearer biomarkers, accelerate drug development and more precise healthcare.
Image Source: Zacks Investment Research
The acquisition also supports Bruker’s expansion into multiomics solutions, including instruments, reagents, software and research services, building on the prior acquisitions of proteomics kits, software and services companies PreOmics and Biognosys.
Industry Prospects Favoring Bruker Stock
Per a research report, the global metabolomics services market is estimated to be valued at $3.2 billion in 2025 and expand at a compound annual growth rate (CAGR) of 12.5% through 2032. The market’s growth is being led by growing applications of metabolomics in personalized medicines, drug discovery and development, biomarker discovery, nutrigenomics, and other fields such as toxicology and cancer. The rising R&D investments in pharmaceutical and biotechnology companies also contribute.
More Updates From Bruker
At the 73rd Conference on Mass Spectrometry and Allied Topics, Bruker announced significant advances in ultra-high sensitivity 4D-Proteomics with the introduction of the timsUltra AIP mass spectrometer. The breakthrough Athena Ion Processor technology further enhances the extreme sensitivity of timsTOF UltraPASEF methods for key biological and clinical research problems with very low sample amounts.
BRKR Stock Price Performance
Over the past three months, Bruker shares have declined 13.9% compared with the industry’s 14.3% fall.
BRKR’s Zacks Rank and Key Picks
Bruker currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Hims & Hers Health (HIMS - Free Report) and Cencora (COR - Free Report) . While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 44.6% in the past year compared with the industry’s 9.6% growth. Its earnings yield of 8.5% compares comfortably with the industry’s 0.5% yield. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Hims & Hers Health shares have surged 158% in the past year. Estimates for the company’s 2025 earnings per share have jumped 4.3% to 73 cents in the past 30 days. HIMS’ earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.
Estimates for Cencora’sfiscal 2025 earnings per share have increased 1.3% to $15.75 in the past 30 days. Shares of the company have jumped 22.1% in the past year against the industry’s 21% fall. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%.